H2O.ai Launches H2O AI Hybrid Cloud
26.1.2021 19:19:00 EET | Business Wire | Press release
H2O.ai announces H2O AI Hybrid Cloud, an end-to-end AI platform that enables organizations to build rapidly, share, and use AI models and applications.
An innovative new platform, H2O AI Hybrid Cloud, empowers anyone to innovate and use AI to make better forecasts, streamline operations, reduce risk, and personalize customer experiences. It contains capabilities and automation across the entire data science lifecycle, including connecting to and preparing data, building and explaining models, deploying and operating models, and building and sharing AI applications.
“AI is central to AT&T’s mission to deliver wireless, broadband, and software-based video to our customers. We’ve deployed hundreds of AI models to support those products and services, such as to protect our customers by scoring transactions in real-time for the likelihood of fraud. Collaborating with H2O around their open source tools including H2O Wave and H2O AI Hybrid Cloud will let us expand those capabilities across AT&T.” – Mark Austin, Vice President of Data Science, AT&T
H2O AI Hybrid Cloud is deployed on Kubernetes, enabling customers to operate on any cloud, such as Microsoft Azure or on-premises infrastructure.
The platform features over 200 data connectors, automatic data visualization, automatic feature engineering, AutoML for tabular, time-series, text, image, and video data, and machine learning operations technology to help organizations govern and continuously improve models. H2O AI Hybrid Cloud is integrated with Snowflake, enabling data engineers to make AI models and score records using their preferred language -- SQL.
"It used to take large teams of expert data scientists months, or longer, to develop a single model, but today, with Snowflake’s extensibility capabilities and H2O's AutoML technology, data engineers can rapidly build and deploy their models and score records, all from within Snowflake using SQL." - Snowflake Director of Product Management, Torsten Grabs
The H2O AI Hybrid Cloud integrates with the recently released H2O Wave and is built for organizations that want to put AI into their business users’ hands. An open-source lightweight Python development framework, this platform makes it easy for developers, data scientists, and machine learning engineers to make sophisticated applications that leverage AI models.
“The future is no-touch, seamless, frictionless automation, supported by deep insights. Powered by H2O AI Hybrid Cloud, Arogya Mitra Sejati is bringing to life Arogya, a deep insights based automated supply chain platform - optimized for healthcare.” - Vijay Sarashetti, Cofounder and CTO, Arogya
H2O AI Hybrid Cloud also provides an AppStore, enabling organizations to publish and share the AI applications they build with H2O Wave. The AppStore deploys with a set of pre-built applications, such as Automatic Insights, Recommendations, and LIBOR, which organizations can use to put AI into production even faster.
“AI is transforming the world. Organizations are adopting AI at increasing rates and need holistic, open and automated platforms to make world-class AI models and applications rapidly. H2O AI Hybrid Cloud enables organizations to make AI for virtually any use case, streamline machine learning operations and democratize AI across the organization.” -Sri Ambati, CEO, H2O.ai
To meet hybrid and multi-cloud requirements for enterprises, Red Hat OpenShift will certify the platform early this year.
“Red Hat OpenShift, the industry’s leading enterprise-grade, fully-supported Kubernetes platform, is optimized for H2O Driverless AI and H2O Open Source, making it easier for customers to deploy and manage H2O.ai products across the hybrid cloud. We are working closely with H2O.ai as they seek to certify H2O AI Hybrid Cloud on OpenShift in order to continue building on this momentum.” - Joe Fernandes, Vice President and General Manager, Cloud Platforms, Red Hat
About H2O.ai
H2O.ai is a leading AI technology company that enables organizations to rapidly build world-class AI models and applications. We continue to reimagine what is possible with artificial intelligence and deliver new platforms and technologies to put responsible AI into the hands of more users.
Our vision is to democratize AI by making it easier for individuals to build and access world-class and responsible AI. To achieve this vision, we’re creating a culture of responsible and engaged makers: community, customers, partners, entrepreneurs, and our own “makers,” and we’re enabling them with the technology to “make.” H2O is a leading open-source data science and machine learning platform used by nearly half of the Fortune 500 and trusted by over 20,000 organizations and hundreds of thousands of data scientists around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005850/en/
Contact information
Ana Visneski
anastacia.visneski@h2o.ai
206-498-1085
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
